ANNIE VU: Open Payments
NPI 1336738046 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,301 in 346 payments from 50 companies in 2025. Trend: 2023 $918 · 2024 $6,270 · 2025 $8,301
Food & beverage: $7,274Long term medical supply or device loan: $698Education: $347
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 24 | $1,080 |
| AstraZeneca Pharmaceuticals LP | 23 | $569 |
| E.R. Squibb & Sons, L.L.C. | 27 | $568 |
| Janssen Biotech, Inc. | 19 | $412 |
| Incyte Corporation | 28 | $394 |
| Celgene Corporation | 27 | $371 |
| ABBVIE INC. | 15 | $297 |
| SEAGEN INC. | 3 | $291 |
| Merck Sharp & Dohme LLC | 11 | $256 |
| Eisai Inc. | 11 | $252 |
Products named: KISQALI, OPDIVO, REBLOZYL, CALQUENCE, Lenvima, JAKAFI, IMFINZI, EPKINLY.
Industry payments across CA — which companies pay providers there.
